Bluejay Diagnostics, Inc. (BJDX)
NASDAQ: BJDX · Real-Time Price · USD
0.9390
-0.0209 (-2.18%)
At close: Sep 29, 2026, 4:00 PM EDT
0.9200
-0.0190 (-2.02%)
After-hours: Sep 29, 2026, 7:43 PM EDT
Bluejay Diagnostics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
4.20M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 249.04K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Trinity Biotech | 43.79M |
| WORK Medical Technology Group LTD | 10.72M |
| INVO Fertility | 7.53M |
| Intelligent Bio Solutions | 4.22M |
| VolitionRx | 2.46M |
| 20/20 Biolabs | 2.04M |
| Nexalin Technology | 217.16K |
| Adagio Medical Holdings | 137.00K |
BJDX News
- 21 days ago - Bluejay Diagnostics and Lovell Government partner to access federal healthcare - TheFly
- 21 days ago - Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets - GlobeNewsWire
- 6 weeks ago - Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization - GlobeNewsWire
- 2 months ago - Bluejay Diagnostics completes enrollment in SYMON-II study - TheFly
- 2 months ago - Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study - GlobeNewsWire
- 3 months ago - Bluejay Diagnostics files to sell 11.22M shares of common stock for holders - TheFly
- 3 months ago - Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 3 months ago - Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire